stars 1 stars 2 stars 3

Mitocholine has discovered, patented, and is commercializing a groundbreaking nutritional composition for everyday intake that effectively addresses multiple age-related challenges and nutritional deficiencies. A rapidly mounting body of research has shown that age related cognitive decline is caused by diminishing cell energetics: a decline in the energy level in the brain cells. Our first product is a breakthrough formula that increases metabolic receptiveness to insulin in the brain, bringing more glucose into the brain cells, and optimizes its utilization while generating energy (ATP). Our first product is in a proof-of-concept human clinical study involving people with mild cognitive impairment (MCI) and is expected to show strong promise to improve executive function and various markers related to cell energetics. There is a rapidly growing body of evidence that improving cell energetics could be a means of impeding the onset of dementia. Related compositions and a pipeline of additional products will demonstrate additional, mechanistically related benefits for people of all ages.

Mitocholine Ltd Questions

The Mitocholine Ltd annual revenue was $3 million in 2026.

Larisa Andreeva is the Managing Director of Mitocholine Ltd.

2 people are employed at Mitocholine Ltd.

Mitocholine Ltd is based in London, England.

The NAICS codes for Mitocholine Ltd are [54171, 541714, 541, 54, 5417].

The SIC codes for Mitocholine Ltd are [87, 873].

Top Mitocholine Ltd Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users